Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Betticher, DC; Hsu Schmitz, SF; Tötsch, M; Hansen, E; Joss, C; von Briel, C; Schmid, RA; Pless, M; Habicht, J; Roth, AD; Spiliopoulos, A; Stahel, R; Weder, W; Stupp, R; Egli, F; Furrer, M; Honegger, H; Wernli, M; Cerny, T; Ris, HB; Swiss Group for Clinical Cancer Research (SAKK).
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
Br J Cancer. 2006; 94(8):1099-1106
Doi: 10.1038/sj.bjc.6603075
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Tötsch Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles of docetaxel 85 mg m-2 (day 1) plus cisplatin 40 or 50 mg m-2 (days 1 and 2). Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported), with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months, respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At 3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65% of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%) and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel-cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - surgery
- Chemotherapy, Adjuvant -
- Cisplatin - therapeutic use
- Combined Modality Therapy -
- Disease-Free Survival -
- Female -
- Follow-Up Studies -
- Humans -
- Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - surgery
- Male -
- Middle Aged -
- Neoplasm Recurrence, Local -
- Neoplasm Staging -
- Prognosis -
- Recurrence -
- Risk Assessment -
- Survival Rate -
- Taxoids - therapeutic use
- Time Factors -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- chemotherapy activity
- downstaging
- long
- term survivor
- stage IIIA NSCLC